drugset
drugset / Trial / NCT00066989

Safety Study of an Intravenous Staphylococcus Aureus Immune Globulin (Human), [Altastaph] in Low-Birth-Weight-Neonates

NCT00066989 ↗

Phase 2 Completed 200 enrolled Nabi Biopharmaceuticals
RandomizedParallel-groupDouble-blindPrevention

Summary

The main objective will be to test the safety of two intravenous infusions of Altastaph, a human immunoglobulin product. The study will also test the ability of Altastaph to protect against S. aureus infection.

Timeline

Start
2003-07
Primary completion
2004-08
Completion
2004-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Staphylococcus Aureus Immune Globulin (Human) Protein / enzyme biologic 5 % Intravenous

Indications

staphylococcal infection